Goldenwell Biotech, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $5,220 for the three months ending June 30, compared to a net loss of $49,920 for the same period in 2024. For the first half of 2025, the company recorded a net loss of $39,596, a significant reduction from the $80,897 loss reported in the first half of 2024. The company generated service revenue of $37,500 during the second quarter, while sales revenue remained at $0, consistent with the previous year. Overall, the gross profit for the quarter was $37,500, a decrease from $70 in the prior year.
In terms of operational expenses, Goldenwell Biotech reported a reduction in general and administrative expenses, which totaled $40,620 for the second quarter of 2025, down from $47,890 in the same quarter of 2024. For the first half of 2025, these expenses were $72,896, compared to $76,846 in the first half of 2024. The company’s total assets increased to $251,295 as of June 30, 2025, up from $224,192 at the end of 2024, primarily due to an increase in cash reserves, which rose to $76,507 from $49,404.
Goldenwell Biotech's liabilities also saw a notable increase, with total liabilities rising to $338,133 from $271,433 at the end of 2024. The company’s stockholders' equity decreased to $(86,838) from $(47,241), reflecting ongoing financial challenges. The company has accumulated a net loss of $1,399,241 since its inception, raising concerns about its ability to continue as a going concern without additional capital. The company has indicated that it plans to raise funds through debt or equity offerings, although there is no guarantee of success in these efforts.
The company remains in the development stage, focusing on research and development, production, and sales of healthcare and supplement products. As of June 30, 2025, Goldenwell Biotech had no significant customer counts or user statistics to report, and it has not yet launched any new products. The company is currently assessing its operational capabilities, including the construction of manufacturing facilities, which it estimates will require approximately $5 million and take about one year to complete. The management has expressed that achieving further sales and financing is critical for the company's future operations and growth.
About GOLDENWELL BIOTECH, INC.
Goldenwell Biotech, Inc. is an early-stage company focused on research, development, and production of nutraceuticals and dietary supplements. It licenses proprietary technology for health products, including peptides and plant extracts, targeting health-conscious consumers. The company operates with minimal assets, relies on external financing, and emphasizes innovation in bioactive health solutions within the wellness market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.